Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years at the time of signing the informed consent form
Must be able to adhere to the study visit schedule and other protocol requirements
Must have a documented diagnosis of B-cell CLL
Must be relapsed or refractory to at least 1 regimen for treatment of CLL. At least one of the prior treatments must have included a purine analog-based or bendamustine-based regimen
Must have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2.
You may not be if
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
Active infections requiring systemic antibiotics
Systemic treatment for B-cell CLL within 28 days of initiation of lenalidomide treatment
Alemtuzumab therapy within 120 days of initiating lenalidomide treatment
Prior therapy with lenalidomide
History of grade 4 rash due to prior thalidomide treatment
Planned autologous or allogeneic bone marrow transplantation
Central nervous system (CNS) involvement as documented by spinal fluid cytology or imaging.
Uncontrolled hyperthyroidism or hypothyroidism
Venous thromboembolism within 12 months
≥ Grade 2 neuropathy
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
Disease transformation \[i.e. Richter's Syndrome (lymphomas) or prolymphocytic leukemia\]
Participation in any clinical study or having taken any investigational therapy within 28 days prior to initiating lenalidomide therapy
